Stay updated with breaking news from Ralf Smit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners.
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as
Strategic Funding to advance Drug Candidate Jan 14 2021 Read 170 Times Biologics manufacturer eleva GmbH has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. The company also announced the addition of Dr. Ralf Smit to its Executive Board. The Freiburg-based company developed its moss-based platform to produce biologics like antibodies, replacement enzymes, or fusion toxins. The funding from ZFHN...
Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ — Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive Board. Eleva has been utilizing its unique moss-based platform to produce novel drugs. ZFHN, ...
(1) FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive Board. Eleva has been utilizing its unique moss-based platform to produce novel drugs. ZFHN, an investor in local start-ups, is now providing up to EUR 60 million to help take CPV-...